Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Tian Ran Zhu"'
Autor:
Tian Ran Zhu, MD, Diana Zarowin, BS, Adnan Mir, MD, PhD, Julia Gittler, MD, Caroline Halverstam, MD
Publikováno v:
JAAD Case Reports, Vol 48, Iss , Pp 144-147 (2024)
Externí odkaz:
https://doaj.org/article/8957ed6bfd1d46cc9b34efb4da1164d1
Autor:
Onjona B. Hossain, BS, Daniel R. Antohi, BA, Tian Ran Zhu, MD, Michael Occidental, MD, Amin Bijal, MD, Benedict Wu, DO, PhD
Publikováno v:
JAAD Case Reports, Vol 44, Iss , Pp 110-112 (2024)
Externí odkaz:
https://doaj.org/article/dd97437a2faf4e718a3b218d12c494ba
Autor:
Rex H. Lee, Ritu Roy, Hua Li, Aaron Hechmer, Tian Ran Zhu, Adila Izgutdina, Adam B. Olshen, Daniel E. Johnson, Jennifer R. Grandis
Publikováno v:
PLoS ONE, Vol 18, Iss 3 (2023)
There are currently no clinical strategies utilizing tumor gene expression to inform therapeutic selection for patients with head and neck squamous cell carcinoma (HNSCC). One of the challenges in developing predictive biomarkers is the limited chara
Externí odkaz:
https://doaj.org/article/fa000583673044f0affae32431c0d9cc
Publikováno v:
JAAD Case Reports, Vol 15, Iss , Pp 76-79 (2021)
Externí odkaz:
https://doaj.org/article/512881a29cef46129dceb21520467965
Autor:
Mehdi Bouhaddou, Rex H. Lee, Hua Li, Neil E. Bhola, Rachel A. O’Keefe, Mohammad Naser, Tian Ran Zhu, Kelechi Nwachuku, Umamaheswar Duvvuri, Adam B. Olshen, Ritu Roy, Aaron Hechmer, Jennifer Bolen, Stephen B. Keysar, Antonio Jimeno, Gordon B. Mills, Scott Vandenberg, Danielle L. Swaney, Daniel E. Johnson, Nevan J. Krogan, Jennifer R. Grandis
Publikováno v:
JCI Insight, Vol 6, Iss 20 (2021)
The epidermal growth factor receptor (EGFR) inhibitor cetuximab is the only FDA-approved oncogene-targeting therapy for head and neck squamous cell carcinoma (HNSCC). Despite variable treatment response, no biomarkers exist to stratify patients for c
Externí odkaz:
https://doaj.org/article/0965f45254de4190931a8e6473149c38
Autor:
Daniel Bradley, MD, Thomas Willson, MD, Jessica B. Chang, MD, Brad Gandolfi, MD, Tian Ran Zhu, MD, James P. Bradley, MD, Justine C. Lee, MD, PhD
Publikováno v:
Plastic and Reconstructive Surgery, Global Open, Vol 7, Iss 9, p e2388 (2019)
Summary:. Bony ankylosis of the temporomandibular joints (TMJ) occurs in up to 28% of patients with syndromic mandibular dysostoses. Release of complete osseous ankylosis is particularly challenging due to the lack of tissue planes separating the man
Externí odkaz:
https://doaj.org/article/f3f50a28ee7447778d4a4de131d69c7e
Autor:
Yssra S. Soliman, Karolina Mieczkowska, Tian Ran Zhu, Onjona Hossain, Tian Hao Zhu, David H. Ciocon, Ramone F. Williams
Publikováno v:
British Journal of Dermatology. 187:597-599
Autor:
Divya J. Aickara, Julia Arzeno︎, Smita Awashti, Safiyyah Bhatti, Paul Blackcloud, Lawrence S. Chan, Colleen Cotton, Lawrence Eichenfield, Kayla Fourzali, Jennifer Fernandez, John Frew, Rachel Shireen Golpanian, David Grand, Takashi Hashimoto, Jason Ezra Hawkes, Aleksi Hendricks, Penelope Hirt, Marcia Hogeling, Jennifer Hsiao, Victor Huang, Jonwei Hwang, Joanna Jaros, Yana Kost, Christina Kursewicz, Dylan E. Lee, Griffin R. Lee, Hadar Lev-Tov, Peter Lio, Mary E Logue, Haruyo Nakajima-Adachi, Jennifer Ornelas, Daniela Sanchez, Vivian Y. Shi, Michiko Shimoda, Raja Sivamani, Aimee Caroline Smidt, Kyle Tegtmeyer, Alexis Tracy, Khiem Tran, Masako Toda, Marta Turowski, Michelle Vy, Claire Wilson, Peggy A Wu, Hera Wu, Joseph Yardman-Frank, Gil Yosipovitch, Jeffrey Zhao, Tian Hao Zhu, Tian Ran Zhu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b563652bb36059286a2effaf9a193af
https://doi.org/10.1016/b978-0-323-84744-5.00031-0
https://doi.org/10.1016/b978-0-323-84744-5.00031-0
Autor:
Jennifer Bolen, Neil E. Bhola, Stephen B. Keysar, Umamaheswar Duvvuri, Aaron Hechmer, Danielle L. Swaney, Antonio Jimeno, Mohammad Naser, Daniel Johnson, Kelechi Nwachuku, Tian Ran Zhu, Jennifer R. Grandis, Ritu Roy, Nevan J. Krogan, Rex H. Lee, Scott R. VandenBerg, Rachel A. O'Keefe, Adam B. Olshen, Mehdi Bouhaddou, Hua Li, Gordon B. Mills
Publikováno v:
JCI Insight
JCI insight, vol 6, iss 20
JCI insight, vol 6, iss 20
The epidermal growth factor receptor (EGFR) inhibitor cetuximab is the only FDA-approved oncogene-targeting therapy for head and neck squamous cell carcinoma (HNSCC). Despite variable treatment response, no biomarkers exist to stratify patients for c